Long Opportunity Emerges as Sangamo Leverages Gene Editing to Hemophilia …

Published November 28, 2012

Long Opportunity Emerges As Sangamo Leverages Gene Editing To Hemophilia …

Filed under: drug treatment news articles

I have no business relationship with any company whose stock is mentioned in this article. (More…) The odds of a … It might be more acceptable to patients than drug therapy, which can cost up to $ 40,000 per year and cause toxic side effects. At the …
Read more on Seeking Alpha

Novartis drug Exjade(R) recommended by CHMP for EU approval to treat …

Filed under: drug treatment news articles

Novartis International AG / Novartis drug Exjade® recommended by CHMP for EU approval to treat patients with non-transfusion-dependent thalassemia syndromes . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for …
Read more on Reuters

Today's Market News To Trade On: 5 Stocks Moving On News

Filed under: drug treatment news articles

As the highlights from this morning's article indicate, there are still bright spots in the market, it is simply a matter of finding them and hitching a ride for the rise. We have economic news due out … In the Phase III Trial, the company stated …
Read more on Seeking Alpha